BridgeBio Pharma, Inc. announced new data from the Phase III ATTRibute-CM study at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology… read more.
Blood tests to detect potential signs of prostate cancer likely reduce the risk of dying from prostate cancer, an updated Cochrane review finds. This is a shift from… read more.
New research presented at this year’s European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people… read more.
ImmunityBio announced results from two indirect treatment comparison (ITC) analyses presented at the 2026 American Urological Association (AUA) Annual Meeting evaluating nogapendekin alfa inbakicept-pmln (NAI, Anktiva) plus Bacillus Calmette–Guérin (BCG)… read more.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that final data from the Phase 3 AcceleRET-Lung clinical trial of… read more.
Krystal Biotech announced that, on May 15, 2026, the United Kingdom MHRA granted marketing authorization to Vyjuvek (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis… read more.
Researchers report that vitamin D deficiency is associated with more moderate to severe pain after breast cancer surgery. The findings were published online on May 19, 2026 in… read more.
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, taken during the first trimester of pregnancy are not associated with an increased risk of major birth defects, according… read more.
Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30,… read more.
At the 2026 ASCO Annual Meeting, Boehringer Ingelheim presented new data from across its oncology clinical development program, including patient-reported outcomes (PROs) for HERNEXEOS® (zongertinib tablets) in HER2… read more.
Incyte announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an… read more.
U.S. teens report far less anabolic steroid use than they did two decades ago, but creatine use has risen rapidly in recent years, according to a new University… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
